IRVINE, CA--(Marketwired - Aug 7, 2013) - Biomerica, Inc. (OTCBB: BMRA) announced today that it has received approval to market and sell its H. Pylori and Parathyroid Hormone (PTH) diagnostic tests in Mexico. The company also announced that it has appointed a new distributor in Mexico with over 35 years of experience and 200 employees overall. 

Helicobacter pylori (H. pylori) is a bacterium responsible for over 85% of ulcers. It is estimated that the worldwide anti-ulcer market is over $9.5 billion. Epidemiological studies have shown that the H. pylori infection is widespread, affecting over one billion people worldwide. The disease affects both men and women and nearly all duodenal ulcer patients and over 80% of stomach ulcer patients are infected with the bacterium. In addition to peptic ulcer disease, H. pylori infection has also been shown to be a significant risk factor for stomach cancer. Biomerica's H. pylori test allows laboratories to automate the testing for H. pylori in a quick and cost effective manner. 

Parathyroid hormone (PTH) controls calcium, phosphorus, and vitamin D levels in the blood and bone. Release of PTH is controlled by the level of calcium in the blood. Low blood calcium levels cause increased PTH to be released, while high blood calcium levels block PTH release. PTH tests are usually ordered when someone has symptoms associated with hypercalcemia or hypocalcemia, such as: Fatigue, Nausea, Abdominal pain and Thirst Muscle cramps. A doctor may also order a PTH when a person has a chronic condition such as kidney disease. Using Biomerica's PTH test, laboratories can automate the testing for PTH in a rapid and cost effective manner. 

"We are excited about these regulatory approvals and the addition of our new Mexico distributor," said Zackary Irani, CEO, Biomerica. "With a potential market of over 3,500 clinical labs, these approvals will allow our new distributor to sell and market our product throughout the country."

Biomerica is also seeking approval for several of its other products in Mexico. 

About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses is on products for Diabetes, Gastrointestinal Disease and esoteric testing.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.